Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

donor-derived haploidentical IL-21-expanded natural killer cells

A population of ex-vivo human interleukin-21 (IL-21) expanded donor-derived human leukocyte antigen (HLA) haploidentical natural killer (haploNK) cells, with potential immunomodulating and antineoplastic activities. Upon administration in patients undergoing HLA-haploidentical hematopoietic cell transplantation, the donor-derived haploidentical IL-21-expanded NK cells target, lyse and destroy tumor cells. IL-21 promotes sustained ex vivo proliferation of human NK cells and enhances its cytotoxic activity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic IL-21-expanded haploNKs
donor-derived haploidentical IL-21-expanded NKs
donor-derived IL-21 expanded NK cells
IL-21-treated HLA-haploidentical donor NK cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search